Mark Steven Link

Mark Steven Link

Auto-generated profile, based on publicly available information

Mark Steven Link

UT Southwestern Medical Center, Dallas, Texas

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
MLMark S. Link
Mark S. Link
RGRobert P. Giugliano
Robert P. Giugliano
CRChristian T. Ruff
Christian T. Ruff
BSBenjamin M. Scirica
Benjamin M. Scirica
HHHeikke Huikuri
Heikke Huikuri
EBEugene Braunwald
Eugene Braunwald
Background—: Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagulation is controversial. In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality. However, detailed analyses by AF pattern have not been reported. Methods and Results—: The 21 105 patients were categorized as having paroxysmal (<7 days duration), persistent (≥7 days but <1 year), or permanent (≥1 year or failed cardioversion) AF patterns at randomization. Efficacy and safety outcomes were evaluated during the 2.8 years median follow-up and compared by AF pattern. The primary end point of stroke/systemic embolic event was lower in those patients with paroxysmal AF (1.49%/year), compared with persistent (1.83%/year; P -adj =0.015) and permanent AF (1.95%/year; P -adj =0.004). Overall, all-cause mortality also was lower with paroxysmal (3.0%/year) compared with persistent (4.4%/year; P -adj <0.001) and permanent AF (4.4%/year; P -adj <0.001). Annualized major bleeding rates were similar across AF patterns (2.86% versus 2.65% versus 2.73%). There was no effect modification by treatment assignment. Conclusions—: In ENGAGE AF-TIMI 48 trial, patients with paroxysmal AF suffered fewer thromboembolic events and deaths compared with those with persistent and permanent AF. The efficacy and safety profile of edoxaban as compared with warfarin was consistent across the 3 patterns of AF. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00781391.

1 June 2004 in JACC
Verified
Journal Article
Closed access
MLMark S Link
Mark S Link
AHAnne S Hellkamp
Anne S Hellkamp
NEN.A.MArk Estes
N.A.MArk Estes
EOE.JOhn Orav
E.JOhn Orav
KEKenneth A Ellenbogen
Kenneth A Ellenbogen
GLGervasio A Lamas
Gervasio A Lamas

1 March 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
WWWeijia Wang
Weijia Wang
ZLZhesi Lian
Zhesi Lian
EREthan J. Rowin
Ethan J. Rowin
BMBarry J. Maron
Barry J. Maron
MMMartin S. Maron
Martin S. Maron
MLMark S. Link
Mark S. Link
Background—: The prognostic significance of nonsustained ventricular tachycardia (NSVT) in patients with hypertrophic cardiomyopathy is incompletely resolved. Methods and Results—: The study group comprised 160 patients with implantable cardioverter defibrillators (ICDs), of whom 94 patients had 24- to 48-hour ambulatory monitoring preimplant. ICDs were interrogated and ambulatory ECGs monitored for NSVT episodes, with associations between NSVT- and ICD-treated ventricular arrhythmias examined. Eighty-six (54%) patients had runs of NSVT, including 17 before implant on ambulatory monitoring, 44 after ICD implantation, and 22 on both. Agreement between preimplant ambulatory monitoring and ICD interrogation for detecting NSVT was poor (κ=0.18). Eighteen of 86 patients (21%) with NSVT and 6 of 74 patients (8%) without NSVT experienced ICD-treated ventricular tachycardia (VT)/ventricular fibrillation (VF). NSVT was significantly associated with ICD-treated VT/VF (adjusted hazard ratio, 3.98; 95% confidence interval, 1.41–11.29; P =0.0093). ICD-treated VT/VF was associated with NSVT runs at a rate >200 beats per minute (adjusted hazard ratio, 15.63; 95% confidence interval, 4.01–60.89; P 7 beats (adjusted hazard ratio, 6.26; 95% confidence interval, 2.02–19.41; P =0.0015). Repetitive runs of NSVT were also associated with ICD-treated VT/VF (adjusted hazard ratio, 9.22; 95% confidence interval, 2.53–33.60; P =0.0008). Slower (≤200 beats per minute), shorter (≤7), or a single run of NSVT were not associated with ICD-treated ventricular arrhythmias. Conclusions—: On extended monitoring, NSVT was independently associated with ICD-treated ventricular arrhythmias, supporting the importance of NSVT in hypertrophic cardiomyopathy risk stratification. Faster rate (>200 beats per minutes), longer (>7 beats), and repetitive runs of NSVT were more highly predictive of ICD-treated VT/VF.

1 May 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
ARAnna G. Rosenblatt
Anna G. Rosenblatt
CAColby Ayers
Colby Ayers
ARAnjali Rao
Anjali Rao
SHStacey J. Howell
Stacey J. Howell
NHNicholas S. Hendren
Nicholas S. Hendren
SDSandeep R. Das
Sandeep R. Das
Background: New-onset atrial fibrillation (AF) in patients hospitalized with COVID-19 has been reported and associated with poor clinical outcomes. We aimed to understand the incidence of and outcomes associated with new-onset AF in a diverse and representative US cohort of patients hospitalized with COVID-19. Methods: We used data from the American Heart Association COVID-19 Cardiovascular Disease Registry. Patients were stratified by the presence versus absence of new-onset AF. The primary and secondary outcomes were in-hospital mortality and major adverse cardiovascular events (MACE; cardiovascular death, myocardial infarction, stroke, cardiogenic shock, and heart failure). The association of new-onset AF and the primary and secondary outcomes was evaluated using Cox proportional-hazards models for the primary time to event analyses. Results: Of the first 30 999 patients from 120 institutions across the United States hospitalized with COVID-19, 27 851 had no history of AF. One thousand five hundred seventeen (5.4%) developed new-onset AF during their index hospitalization. New-onset AF was associated with higher rates of death (45.2% versus 11.9%) and MACE (23.8% versus 6.5%). The unadjusted hazard ratio for mortality was 1.99 (95% CI, 1.81–2.18) and for MACE was 2.23 (95% CI, 1.98–2.53) for patients with versus without new-onset AF. After adjusting for demographics, clinical comorbidities, and severity of disease, the associations with death (hazard ratio, 1.10 [95% CI, 0.99–1.23]) fully attenuated and MACE (hazard ratio, 1.31 [95% CI, 1.14–1.50]) partially attenuated. Conclusions: New-onset AF was common (5.4%) among patients hospitalized with COVID-19. Almost half of patients with new-onset AF died during their index hospitalization. After multivariable adjustment for comorbidities and disease severity, new-onset AF was not statistically significantly associated with death, suggesting that new-onset AF in these patients may primarily be a marker of other adverse clinical factors rather than an independent driver of mortality. Causality between the MACE composites and AF needs to be further evaluated.

1 May 2003 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
MLMark S. Link
Mark S. Link

25 January 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
AGAlan S. Go
Alan S. Go
PDPatrice Desvigne-Nickens
Patrice Desvigne-Nickens
CAChristopher D. Anderson
Christopher D. Anderson
BCBarbara Casadei
Barbara Casadei
SASana M. Al-Khatib
Sana M. Al-Khatib
Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected until complications such as stroke or heart failure occur. Hence, the public and clinicians have an intense interest in detecting AF earlier. However, the most appropriate strategies to detect undiagnosed AF (sometimes referred to as subclinical AF) and the prognostic and therapeutic implications of AF detected by screening are uncertain. Our report summarizes the National Heart, Lung, and Blood Institute’s virtual workshop focused on identifying key research priorities related to AF screening. Global experts reviewed major knowledge gaps and identified critical research priorities in the following areas: (1) role of opportunistic screening; (2) AF as a risk factor, risk marker, or both; (3) relationship between AF burden detected with long-term monitoring and outcomes/treatments; (4) designs of potential randomized trials of systematic AF screening with clinically relevant outcomes; and (5) role of AF screening after ischemic stroke. Our report aims to inform and catalyze AF screening research that will advance innovative, resource-efficient, and clinically relevant studies in diverse populations to improve the diagnosis, management, and prognosis of patients with undiagnosed AF.